Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study
Bajema K, Yan L, Li Y, Argraves S, Rajeevan N, Fox A, Vergun R, Berry K, Bui D, Huang Y, Lin H, Hynes D, Lucero-Obusan C, Schirmer P, Cunningham F, Huang G, Aslan M, Ioannou G. Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study. The Lancet Infectious Diseases 2025 PMID: 39848264, DOI: 10.1016/s1473-3099(24)00796-5.Peer-Reviewed Original ResearchRespiratory syncytial virusRespiratory syncytial virus vaccinePositive RSV testVaccine effectivenessRSV testCare encountersSecondary outcomesEmergency departmentRSV-associated hospitalisationsMedian follow-upUS Food and Drug AdministrationHealth-care useVeterans Health AdministrationRespiratory illness seasonMatched index dateElectronic health recordsLower respiratory tract diseaseRSV-related illnessFood and Drug AdministrationDepartment of Veterans Affairs Cooperative Studies ProgramVeterans Affairs Cooperative Studies ProgramCooperative Studies ProgramRSV infectionMedian ageUS Department
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply